Innocan Pharma Secures Indian Patent for Novel Liposomal CBD Pain Treatment Platform
核心洞察
Innocan Pharma (搜索) has received patent approval in India for its LPT-CBD technology, a liposomal drug delivery platform designed for controlled release of synthetic CBD in chronic pain (搜索) management.
The patented technology, developed in collaboration with Hebrew University (搜索) researchers, represents a potential non-opioid alternative for pain treatment in India's $55 billion pharmaceutical market.
The platform has already received positive feedback from the FDA following a pre-IND meeting, demonstrating promising pharmacokinetics and efficacy in multiple animal models of chronic pain (搜索).
Innocan Pharma (搜索) Corporation has achieved a significant milestone with the approval of its first patent in India for its innovative liposomal CBD injection platform. The patent covers a novel prolonged-release pharmaceutical formulation that encapsulates cannabinoids within liposomes, marking a crucial step forward in the development of non-opioid pain management solutions.
The patented LPT-CBD (Cannabidiol-loaded Liposome Injection Platform) technology enables precise dosing and sustained release of synthetic CBD into the bloodstream. This advancement comes at a strategic time, as the company seeks to establish its presence in India's pharmaceutical market, valued at approximately US $55 billion.
Scientific Innovation and Development
The technology emerged from a collaboration between Innocan and renowned researchers from the Hebrew University (搜索) in Jerusalem. Professor Chezy Barenholz and Dr. Ahuva Cern spearheaded the development of the liposomal drug delivery platform, which maximizes the bioavailability and therapeutic effects of cannabinoids through prolonged exposure.
"The approval of this patent is a testament to the dedication and expertise of our development teams in driving innovation," stated Professor Barenholz, who heads Innocan's Advisory Board. "LPT-CBD is the first drug product in our pipeline that we are currently advancing under this intellectual property portfolio."
Clinical Progress and Regulatory Advancement
The platform has already garnered positive feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-IND meeting. Dr. Eyal Kalo, R&D Director at Innocan Pharma (搜索), highlighted the platform's promising results: "LPT-CBD demonstrates sustained pharmacokinetics and has shown efficacy in multiple animal models of chronic pain (搜索)."
Market Impact and Future Prospects
The Indian patent approval strengthens Innocan's global intellectual property portfolio and positions the company to address the growing demand for innovative pain management solutions. CEO Iris Bincovich expressed optimism about the development: "This milestone highlights our innovation, and we look forward to a series of anticipated global patent approvals."
The technology's potential as a non-opioid alternative for chronic pain (搜索) management could significantly impact treatment paradigms, particularly in markets seeking alternatives to traditional opioid-based therapies. The company continues to advance its development program while pursuing additional patent protection in other key markets worldwide.